Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Allowed: RUNX1 t(8;21)

Allowed: CBFB inv(16)

Allowed: BCR t(9;22)

Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor

Must have received: cytarabine-based therapy (cytarabine) — remission induction and at least 1 consolidation cycle

Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle

Must have received: low-dose cytarabine or hypomethylating agent-based therapy (low-dose cytarabine, hypomethylating agent) — at least 2 cycles between CR/CRi and enrollment

Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine [LDAC] or hypomethylating agent [HMA]-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment

Cannot have received: tyrosine kinase inhibitor

Exception: Patients with t(9;22) are ineligible unless unable or unwilling to receive therapy with a tyrosine kinase inhibitor

Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor